For Whom the Biomarkers Toll?

Study finds that a handful of biological indicators can predict a healthy person’s risk of dying within five years.

Written byRina Shaikh-Lesko
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, ROSEMARY VOEGTLIFour blood-based biomarkers can predict a healthy person’s chance of dying within five years, according to a study published this week (February 25) in PLOS Medicine. A team led by investigators at the University of Tartu screened blood samples from more than 17,000 volunteers in Finland and Estonia. The researchers examined more than 100 different biomarkers and found that abnormal levels of just four—alpha-1-acid glycoprotein, albumin, very-low-density lipoprotein particle size, and citrate—were predictive of death risk. Of these, only albumin had previously been tied to mortality.

They then developed a biomarker score that encompassed all four indicators, and found that people with the highest scores were more likely to die within a five-year window. The link persisted even after the research team accounted for factors like age, sex, smoking, drinking, obesity, high blood pressure, and cholesterol levels.

“These biomarkers appeared to actually predict mortality independent of disease,” study coauthor Marcus Perola of the Finland Institute for Health and Welfare told The Telegraph. “These were all apparently healthy people but, to our surprise, it appears these biomarkers show an undetected frailty which people did not know they had.”

The researchers said they next plan to explore what might connect these four biomarkers and account for this hidden frailty, and suggested that their ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies